VJHemOnc is committed to improving our service to you

ASH 2014 | Brentuximib vedotin therapy for Hodgkin lymphoma

VJHemOnc is committed to improving our service to you

Anton Hagenbeek

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses the investigational approaches of brentuximab vedotin, an anti-CD30 antibody conjugated to a cytostatic microtubule-disrupting agent, in the treatment of previously untreated and refractory/relapse patients with Hodgkin lymphoma.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter